Biocon Biologics Secures Canadian Aflibercept Launch
Yesafili Biosimilar Rival To Eylea Can Launch In Canada By Mid-2025 Under Settlement
Biocon has struck a deal with Bayer and Regeneron that will allow the global biosimilars player to launch its Yesafili biosimilar aflibercept rival to Eylea no later than 1 July 2025 in Canada.
